ArticlePloS one2010
Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection.Brazilian journal of veterinary medicine · 2022Article
- The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo.Cancers · 2021Article
- Koala retrovirus diversity, transmissibility, and disease associations.Retrovirology · 2020Article
- XMRV and Public Health: The Retroviral Genome Is Not a Suitable Template for Diagnostic PCR, and Its Association with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Appears Unreliable.Frontiers in public health · 2017Article
- HIV-1 antiretroviral drug therapy.Cold Spring Harbor perspectives in medicine · 2012Review
- Discovery of drugs that possess activity against feline leukemia virus.The Journal of general virology · 2012Article
- Article
- Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection.PloS one · 2012Article
- Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.Nucleic acids research · 2012Article
- Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome.Diagnostic microbiology and infectious disease · 2011Article
- Too soon to translate?Nature medicine · 2011Article
- Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV.Journal of virology · 2011Article
- Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells.Journal of virology · 2011Article
- Differential sensitivities of retroviruses to integrase strand transfer inhibitors.Journal of virology · 2011Article
- No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort.PloS one · 2011Article
- Article
- Crystal structure of XMRV protease differs from the structures of other retropepsins.Nature structural & molecular biology · 2011Article
- Role of raltegravir in the management of HIV-1 infection.HIV/AIDS (Auckland, N.Z.) · 2011Article
- XMRV Discovery and Prostate Cancer-Related Research.Advances in virology · 2011Article
- The xenotropic murine leukemia virus-related retrovirus debate continues at first international workshop.Retrovirology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundXenotropic murine leukemia-related retrovirus (XMRV) is a recently discovered retrovirus that has been linked to human prostate cancer and chronic fatigue syndrome (CFS). Both diseases affect a large fraction of the world population, with prostate cancer affecting one in six men, and CFS affecting an estimated 0.4 to 1% of the population. PRINCIPAL
findingsForty-five compounds, including twenty-eight drugs approved for use in humans, were evaluated against XMRV replication in vitro. We found that the retroviral integrase inhibitor, raltegravir, was potent and selective against XMRV at submicromolar concentrations, in MCF-7 and LNCaP cells, a breast cancer and prostate cancer cell line, respectively. Another integrase inhibitor, L-000870812, and two nucleoside reverse transcriptase inhibitors, zidovudine (ZDV), and tenofovir disoproxil fumarate (TDF) also inhibited XMRV replication. When combined, these drugs displayed mostly synergistic effects against this virus, suggesting that combination therapy may delay or prevent the selection of resistant viruses.
conclusionsIf XMRV proves to be a causal factor in prostate cancer or CFS, these discoveries may allow for rational design of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.